Life science company Impact Naturals joins forces with capital advisory firm DealBox to launch a digital securities offering.
Founded in 2016, DealBox leverages both traditional and blockchain based digital securities to enhance capital formation for early ventures and growth-stage companies. DealBox has packaged hundreds of early-to-mid stage companies, generating millions in both direct and syndicated investments.
Asset Tokenization Gaining Traction
Asset tokenization is gaining traction as more businesses around the world start to embrace security token issuance as part of their capital fundraising exercise. Regulated digital security issuance offers a cost effective and faster alternative to IPOs (Initial Public Offerings).
The digital securities allow for early stage liquidity under the Rule 506(c) of Regulation D promulgated by the U.S. Securities and Exchange Commission, or SEC, under the Securities Act of 1933, as amended (“Securities Act”).
Impact Naturals will use the proceeds to advance the new lines of cannabinoid-based therapeutics.
Therapeutic Application Of Cannabinoids Gaining Popularity
Cannabinoids are compounds found in cannabis. Cannabis contains more than 460 compounds; at least 80 of these are cannabinoids – chemical compounds that interact with cannabinoid receptors in the brain. Many cannabinoids are now used for therapeutic purposes. Since 2019, hemp-derived cannabinoids like cannabidiol (CBD), Cannabigerol (CBG), and Cannabinol (CBN) have gained popularity with their ability to reduce anxiety and decrease pain and inflammation in the body. Research has found that the per capita spending amongst consumers is estimated at $318.88 for cannabinoid-based products.
Impact Naturals Bringing Innovative cannabinoid-based products
Impact Naturals’ unique, pharmaceutical-like approach to product formulation takes advantage of the body’s existing lipid transport system to deliver beneficial components like CBD, CBG & CBN exactly where they’re needed. Called CHYLOSOMA™, this first-in-class process enables Impact Naturals’ formulas to be 500% more bioavailable than CBD oil alone, meaning the body can get a bigger benefit from a smaller dose.
Impact Naturals is a life science company focused on the development of formulation technologies that increase bioavailability of certain compounds such as dietary supplements and hemp-derived cannabinoids. Impact Naturals’ new line of CBD capsules have been formulated to deliver greater absorption, faster uptake, and longer-lasting effects than traditional oral formulations. The new REVIVE™, RESTORE™, and REST™ capsules contain broad-spectrum, high-absorption CHYLOSOMA formulations of CBD with CBG and CBN, alongside ingredients including American Ginseng, Ginkgo Biloba, and Melatonin.
Impact Naturals Takes Digital Route For Future Growth
Impact Naturals will leverage the digital securities offering to bring in new investments.
Impact Naturals states that “advanced digital securities hold the potential to accelerate the path to liquidity along with more flexibility for investors.” The digital security offering will create an opportunity for the holder to become a shareholder and increase the technology needed to further research in the realm of cannabinoids.
Martin Betoni, Impact Naturals Chief Growth Officer, said:
“With Deal Box, we’ve found a capital advisor who’s as innovative in their approach as we are with our own products. Their unique ability to marry digital securities and cutting-edge financial technology with expert strategic and fundraising guidance is exactly what we need at this stage in our company’s growth.”
Commenting on the partnership with Impact Naturals, John Nance, CEO of Deal Box, stated:
“With CBD becoming more popular everyday, we are excited to be backing Impact Naturals with the necessary means to propel their growth and aid in improved cannabinoid treatment. “Impact Naturals has a very unique formulation containing a precise dosage of CBD perfect to influence a natural response within our bodies.”
